Histone deacetylase inhibition in the treatment of heart disease

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Recent work has demonstrated the importance of chromatin remodeling, especially histone acetylation, in the control of gene expression in the heart. Studies in preclinical models suggest that inhibition of histone deacetylase (HDAC) activity - using compounds that show promise in ongoing oncology trials - blunts pathologic growth of cardiac myocytes. Indeed, small-molecule inhibitors of HDACs are members of an evolving class of pharmacologic agents in development for the treatment of several diseases. If proved effective in the treatment of heart disease, HDAC inhibitors could have a significant impact on public health, as cardiovascular disease remains the leading cause of death in the US. This paper reviews understanding of the mechanisms of action of HDAC inhibitors in the heart and summarizes emerging data regarding their effects on disease-related cardiac remodeling and function.

Original languageEnglish (US)
Pages (from-to)53-67
Number of pages15
JournalExpert Opinion on Drug Safety
Volume7
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Histone Deacetylase Inhibitors
Histone Deacetylases
Heart Diseases
Chromatin Assembly and Disassembly
Acetylation
Cardiac Myocytes
Histones
Cause of Death
Cardiovascular Diseases
Public Health
Gene Expression
Growth

Keywords

  • Cardiac hypertrophy
  • Fibrosis
  • Heart failure
  • Histone deacetylases
  • Remodeling

ASJC Scopus subject areas

  • Pharmacology

Cite this

Histone deacetylase inhibition in the treatment of heart disease. / Berry, Jeff M.; Cao, Dian J; Rothermel, Beverly A; Hill, Joseph A.

In: Expert Opinion on Drug Safety, Vol. 7, No. 1, 01.2008, p. 53-67.

Research output: Contribution to journalArticle

@article{9704360caa4c4e4ab1a59ff1ee948fe8,
title = "Histone deacetylase inhibition in the treatment of heart disease",
abstract = "Recent work has demonstrated the importance of chromatin remodeling, especially histone acetylation, in the control of gene expression in the heart. Studies in preclinical models suggest that inhibition of histone deacetylase (HDAC) activity - using compounds that show promise in ongoing oncology trials - blunts pathologic growth of cardiac myocytes. Indeed, small-molecule inhibitors of HDACs are members of an evolving class of pharmacologic agents in development for the treatment of several diseases. If proved effective in the treatment of heart disease, HDAC inhibitors could have a significant impact on public health, as cardiovascular disease remains the leading cause of death in the US. This paper reviews understanding of the mechanisms of action of HDAC inhibitors in the heart and summarizes emerging data regarding their effects on disease-related cardiac remodeling and function.",
keywords = "Cardiac hypertrophy, Fibrosis, Heart failure, Histone deacetylases, Remodeling",
author = "Berry, {Jeff M.} and Cao, {Dian J} and Rothermel, {Beverly A} and Hill, {Joseph A}",
year = "2008",
month = "1",
doi = "10.1517/14740338.7.1.53",
language = "English (US)",
volume = "7",
pages = "53--67",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Histone deacetylase inhibition in the treatment of heart disease

AU - Berry, Jeff M.

AU - Cao, Dian J

AU - Rothermel, Beverly A

AU - Hill, Joseph A

PY - 2008/1

Y1 - 2008/1

N2 - Recent work has demonstrated the importance of chromatin remodeling, especially histone acetylation, in the control of gene expression in the heart. Studies in preclinical models suggest that inhibition of histone deacetylase (HDAC) activity - using compounds that show promise in ongoing oncology trials - blunts pathologic growth of cardiac myocytes. Indeed, small-molecule inhibitors of HDACs are members of an evolving class of pharmacologic agents in development for the treatment of several diseases. If proved effective in the treatment of heart disease, HDAC inhibitors could have a significant impact on public health, as cardiovascular disease remains the leading cause of death in the US. This paper reviews understanding of the mechanisms of action of HDAC inhibitors in the heart and summarizes emerging data regarding their effects on disease-related cardiac remodeling and function.

AB - Recent work has demonstrated the importance of chromatin remodeling, especially histone acetylation, in the control of gene expression in the heart. Studies in preclinical models suggest that inhibition of histone deacetylase (HDAC) activity - using compounds that show promise in ongoing oncology trials - blunts pathologic growth of cardiac myocytes. Indeed, small-molecule inhibitors of HDACs are members of an evolving class of pharmacologic agents in development for the treatment of several diseases. If proved effective in the treatment of heart disease, HDAC inhibitors could have a significant impact on public health, as cardiovascular disease remains the leading cause of death in the US. This paper reviews understanding of the mechanisms of action of HDAC inhibitors in the heart and summarizes emerging data regarding their effects on disease-related cardiac remodeling and function.

KW - Cardiac hypertrophy

KW - Fibrosis

KW - Heart failure

KW - Histone deacetylases

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=38949146658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949146658&partnerID=8YFLogxK

U2 - 10.1517/14740338.7.1.53

DO - 10.1517/14740338.7.1.53

M3 - Article

C2 - 18171314

AN - SCOPUS:38949146658

VL - 7

SP - 53

EP - 67

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 1

ER -